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Background
Despite modern treatment approaches Juvenile Dermato-
myositis (JDM) remains a serious and potentially life
threatening disease. There are few studies which have doc-
umented mortality among large series of cases of JDM
treated with modern therapeutic approaches. The Juvenile
Dermatomyositis National Registry and Repository, UK
and Ireland (JDRR) was established in 2000 to facilitate
research and improve knowledge about JDM.
Methods
Children were recruited through the JDRR cohort study.
Mortality attributed to JDM or its complications was
recorded. A survey of contributors in The Juvenile Dermat-
omyositis Research Group was also conducted to establish
mortality in JDM cases that had not been recruited to the
JDRR study.
Results
245 children (166 females) with myositis have been
recruited to the JDRR. Of these, 208 have a diagnosis of
JDM or JDM with overlap features (148 females). The
total years of JDM disease documented is 1353 patient
years. There have been 2 recorded deaths, a rate of 0.96%
or 0.15 per 100 patient years of disease. However physi-
cians in contributing centres were aware of 1 death attrib-
utable to JDM in cases that could not be recruited to the
study before death.
Conclusion
Mortality due to rare diseases can be difficult to estimate
accurately. Within the UK and Ireland JDRR study, mor-
tality due to JDM since 2000 has been 0.96%. However
this may underestimate deaths as the JDRR does not nec-
essarily recruit all cases of JDM within the UK. JDM
remains a serious a life threatening disease of children
despite modern therapies and specialist care.
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